Linagliptin Advanz Pharma: Uses, Dosage & Side Effects

What Is Linagliptin Advanz Pharma and What Is It Used For?

Linagliptin Advanz Pharma contains the active substance linagliptin, which belongs to a class of medications known as dipeptidyl peptidase-4 (DPP-4) inhibitors, sometimes referred to as “gliptins.” This class of drugs represents an important advancement in the management of type 2 diabetes mellitus, a chronic metabolic condition characterized by insulin resistance and progressive beta-cell dysfunction that affects over 500 million people worldwide according to the International Diabetes Federation (IDF). DPP-4 inhibitors have become one of the most widely prescribed classes of oral antidiabetic agents due to their favorable efficacy-to-side-effect ratio and ease of use.

The mechanism of action of linagliptin centers on the incretin system, a key physiological pathway that regulates blood sugar after meals. When food is consumed, the gut releases two important incretin hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones are responsible for what is known as the “incretin effect” – the phenomenon whereby oral glucose intake stimulates a greater insulin response than the same amount of glucose given intravenously. GLP-1 and GIP act on pancreatic beta cells to stimulate glucose-dependent insulin secretion, meaning they promote insulin release only when blood sugar levels are elevated, significantly reducing the risk of hypoglycemia compared to medications such as sulfonylureas.

In healthy individuals, the incretin hormones GLP-1 and GIP have very short half-lives because they are rapidly broken down by the enzyme dipeptidyl peptidase-4 (DPP-4). The half-life of active GLP-1 is only approximately 1–2 minutes. In patients with type 2 diabetes, the incretin effect is diminished, contributing to impaired insulin secretion after meals. Linagliptin works by selectively and reversibly binding to DPP-4, inhibiting its enzymatic activity by more than 80% at the recommended dose of 5 mg. This inhibition prevents the rapid degradation of GLP-1 and GIP, thereby increasing and prolonging their active concentrations in the bloodstream. The elevated incretin levels result in enhanced glucose-dependent insulin secretion from pancreatic beta cells and simultaneous suppression of glucagon release from alpha cells, both of which contribute to improved blood sugar control.

A particularly noteworthy feature of linagliptin is its unique pharmacokinetic profile among DPP-4 inhibitors. While other members of this class (such as sitagliptin, saxagliptin, alogliptin, and vildagliptin) are primarily excreted through the kidneys and therefore require dose adjustments in patients with renal impairment, linagliptin is predominantly eliminated via the biliary system and feces. Approximately 80% of an orally administered dose of linagliptin is excreted unchanged in the feces, with only about 5% excreted via the kidneys. This makes linagliptin the only DPP-4 inhibitor that does not require dose adjustment in patients with any degree of chronic kidney disease (CKD), including those on hemodialysis. Given that approximately 40% of patients with type 2 diabetes develop CKD during their lifetime, this property represents a significant clinical advantage.

Linagliptin Advanz Pharma is indicated for the treatment of type 2 diabetes mellitus in adults to improve glycemic control, used in combination with diet and exercise. It can be prescribed as:

• Monotherapy: When metformin is unsuitable due to intolerance or contraindication (particularly in patients with significant renal impairment where metformin cannot be used).
• Dual therapy: In combination with metformin, a sulfonylurea, a thiazolidinedione, or insulin, when these medications alone (together with diet and exercise) do not provide adequate glycemic control.
• Triple therapy: In combination with metformin and a sulfonylurea, or metformin and insulin, when these combinations do not provide adequate glycemic control.

The clinical efficacy of linagliptin has been established in multiple randomized controlled trials. In pivotal phase III studies, linagliptin 5 mg once daily demonstrated statistically significant reductions in HbA1c (glycated hemoglobin) compared to placebo. As monotherapy, linagliptin reduced HbA1c by approximately 0.6–0.7% from baseline. When added to metformin, the HbA1c reduction was approximately 0.5–0.6%. These reductions are consistent with those seen with other DPP-4 inhibitors and are clinically meaningful, as each 1% reduction in HbA1c is associated with approximately 21% reduction in diabetes-related deaths, 14% reduction in myocardial infarction, and 37% reduction in microvascular complications according to the United Kingdom Prospective Diabetes Study (UKPDS).

What Should You Know Before Taking Linagliptin Advanz Pharma?

Contraindications

The primary contraindication to Linagliptin Advanz Pharma is hypersensitivity (allergy) to linagliptin or to any of the excipients in the formulation. The excipients include mannitol, pregelatinized starch (maize), maize starch, copovidone, and magnesium stearate, with the film coating containing hypromellose, titanium dioxide (E171), talc, macrogol 6000, and iron oxide red (E172). If you have a known allergy to any of these substances, you must not use this medication.

Serious hypersensitivity reactions have been reported in post-marketing surveillance, including anaphylaxis, angioedema (swelling of the face, lips, tongue, and throat), and exfoliative skin conditions. These reactions typically occur within the first 3 months of treatment, with some cases reported after the first dose. If you experience any signs of a serious allergic reaction, discontinue linagliptin immediately and seek urgent medical attention.

Linagliptin Advanz Pharma is not intended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis (DKA). These conditions require insulin therapy. DPP-4 inhibitors, including linagliptin, have not been studied in type 1 diabetes and would not be expected to be effective due to the fundamentally different pathophysiology of this condition.

Warnings and Precautions

Before starting Linagliptin Advanz Pharma, discuss the following conditions and concerns with your healthcare provider:

• Pancreatitis: Cases of acute pancreatitis, including fatal cases, have been reported with DPP-4 inhibitors. Patients should be informed about the characteristic symptoms of pancreatitis (severe, persistent abdominal pain). If pancreatitis is suspected, linagliptin should be discontinued immediately. Patients with a history of pancreatitis should generally not be prescribed DPP-4 inhibitors. Risk factors for pancreatitis include a history of the condition, gallstones, alcoholism, and very high triglyceride levels.
• Hypoglycemia risk with sulfonylureas or insulin: Linagliptin alone has a low risk of causing hypoglycemia (low blood sugar). However, when used in combination with sulfonylureas (such as glimepiride, glipizide, or glyburide) or insulin, the risk of hypoglycemia is increased. Your doctor may need to reduce the dose of the sulfonylurea or insulin when adding linagliptin to your treatment regimen. Symptoms of hypoglycemia include trembling, sweating, rapid heartbeat, hunger, dizziness, and confusion.
• Heart failure: In the CARMELINA cardiovascular outcome trial, hospitalization for heart failure was evaluated as a secondary endpoint. While overall rates were not significantly different between linagliptin and placebo, patients with pre-existing heart failure (NYHA class I–III) should be monitored. The SAVOR-TIMI 53 trial with another DPP-4 inhibitor (saxagliptin) showed an increased risk of heart failure hospitalization, leading to class-wide monitoring for this outcome, although the CARMELINA trial did not replicate this finding for linagliptin.
• Bullous pemphigoid: Cases of bullous pemphigoid, a rare but serious blistering skin condition, have been reported with DPP-4 inhibitors, including linagliptin. If blisters or erosions develop on the skin, linagliptin should be discontinued and a dermatological evaluation obtained.

Pregnancy and Breastfeeding

Linagliptin Advanz Pharma should not be used during pregnancy. There are no adequate and well-controlled studies of linagliptin in pregnant women. Animal reproduction studies with linagliptin did not reveal evidence of teratogenicity or adverse developmental outcomes at clinically relevant exposures. However, as a precautionary measure, use during pregnancy should be avoided. Insulin is the generally preferred treatment for diabetes management during pregnancy because it does not cross the placenta and allows for the tight glycemic control necessary to reduce the risk of fetal complications.

It is not known whether linagliptin or its metabolites are excreted in human breast milk. Studies in rats have demonstrated excretion of linagliptin and its metabolites into milk. A risk to the breastfed infant cannot be excluded. A decision should be made whether to discontinue breastfeeding or to discontinue linagliptin therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother. Consult your doctor for individualized guidance.

Fertility: No studies on the effect of linagliptin on human fertility have been conducted. Animal studies did not show adverse effects on fertility at doses up to 240 times the maximum recommended human dose.

How Does Linagliptin Advanz Pharma Interact with Other Drugs?

Linagliptin has a relatively favorable drug interaction profile. It is not a clinically relevant inhibitor or inducer of cytochrome P450 (CYP) enzymes at therapeutic concentrations. In vitro studies have shown that linagliptin is a weak competitive inhibitor of CYP3A4, but does not inhibit other CYP isoenzymes at clinically relevant concentrations. Linagliptin is a substrate of the P-glycoprotein (P-gp) transporter and CYP3A4 enzyme, and it weakly inhibits P-gp-mediated transport of digoxin.

The clinical relevance of these properties has been extensively evaluated in pharmacokinetic studies and in large clinical trials. In clinical use, the following interactions deserve attention:

Major Interactions

Rifampicin is the most significant drug interaction with linagliptin. As a potent inducer of both P-glycoprotein and CYP3A4, rifampicin decreases the steady-state AUC (area under the concentration-time curve) of linagliptin by approximately 40% and reduces the peak concentration (Cmax) by approximately 44%. This reduction in exposure may diminish the glucose-lowering efficacy of linagliptin. Other strong P-gp and CYP3A4 inducers, such as carbamazepine, phenobarbital, and phenytoin, would be expected to have similar effects, although these have not been specifically studied. The EMA Summary of Product Characteristics notes that the efficacy of linagliptin may be reduced when used with these agents, and an alternative diabetes therapy should be considered.

Minor Interactions

Overall, the drug interaction potential of linagliptin is low, which is a significant clinical advantage in the treatment of type 2 diabetes, where patients frequently take multiple medications for comorbid conditions such as hypertension, dyslipidemia, and cardiovascular disease. Always inform your healthcare provider about all prescription medications, over-the-counter drugs, and herbal supplements you are taking before starting linagliptin.

What Is the Correct Dosage of Linagliptin Advanz Pharma?

Adults

The simplicity of linagliptin dosing is one of its key practical advantages. Unlike many other diabetes medications, there is no titration period – the full therapeutic dose of 5 mg is initiated from the start of treatment. This straightforward dosing approach contributes to improved patient adherence, which is critically important in chronic disease management. Clinical pharmacology studies have demonstrated that 5 mg once daily produces sustained DPP-4 inhibition of greater than 80% throughout the 24-hour dosing interval, which is considered the threshold for clinically meaningful glucose-lowering efficacy.

The pharmacokinetic properties of linagliptin support once-daily dosing. After oral administration of 5 mg, peak plasma concentrations are reached at approximately 1.5 hours (Tmax). Steady-state plasma concentrations are achieved after the third dose of once-daily dosing. At steady state, the AUC of linagliptin increases approximately 33% compared to a single dose. The intrapatient and interpatient coefficients of variation for AUC are small (12.6% and 28.5%, respectively), indicating consistent and predictable drug exposure.

Renal Impairment

Hepatic Impairment

Children

Elderly

Missed Dose

If you forget to take a dose of Linagliptin Advanz Pharma, take it as soon as you remember on the same day. If you do not remember until it is time for the next dose, skip the missed dose and take the next dose at the regular time. Do not take a double dose to make up for a forgotten dose. If you have any concerns about missed doses, consult your doctor or pharmacist.

Overdose

During controlled clinical trials, single oral doses of up to 600 mg (120 times the recommended daily dose) were administered to healthy subjects without clinically significant adverse effects. In the event of an overdose, standard supportive measures should be employed, including removal of unabsorbed material from the gastrointestinal tract if appropriate, clinical monitoring, and institution of supportive therapy as dictated by the patient’s clinical status. Linagliptin is not expected to be significantly removed by hemodialysis or peritoneal dialysis due to its high degree of protein binding (70–80%) and non-renal elimination. Contact your local poison control center or seek emergency medical attention if you suspect an overdose.

What Are the Side Effects of Linagliptin Advanz Pharma?

The safety profile of linagliptin has been extensively characterized in clinical trials involving more than 10,000 patients and through post-marketing surveillance. In controlled clinical trials, the overall incidence of adverse events with linagliptin 5 mg was similar to placebo. The most commonly reported adverse drug reactions are listed below, categorized by frequency according to the Medical Dictionary for Regulatory Activities (MedDRA) convention.

Pancreatitis: Acute pancreatitis has been reported in post-marketing experience and in clinical trials. In the CARMELINA cardiovascular outcome trial, adjudicated acute pancreatitis was reported in 0.3% of patients in the linagliptin group and 0.1% in the placebo group. Patients should be counseled about the symptoms of pancreatitis: severe persistent abdominal pain that may radiate to the back, often accompanied by nausea and vomiting. If pancreatitis is suspected, linagliptin should be discontinued immediately and appropriate investigations initiated.

Hypoglycemia: When linagliptin is used as monotherapy or in combination with metformin and/or a thiazolidinedione, the incidence of hypoglycemia is similar to placebo (approximately 1%). However, when combined with a sulfonylurea (with or without metformin), the incidence of hypoglycemia increases to approximately 15–23%, and when combined with insulin, it may reach 22–31%. This is due to the additive glucose-lowering effects. To minimize hypoglycemia risk, consider reducing the dose of the sulfonylurea or insulin when adding linagliptin.

Bullous pemphigoid: This is a rare but clinically significant dermatological adverse effect that has been reported with multiple DPP-4 inhibitors. The typical presentation includes large, tense blisters on the skin, often on the trunk and extremities, sometimes preceded by urticarial (hive-like) lesions. The median time to onset has been reported as several months after starting therapy. If bullous pemphigoid is suspected, linagliptin should be discontinued and the patient referred for dermatological evaluation. Treatment with topical or systemic corticosteroids is usually effective after drug discontinuation.

Cardiovascular safety: The cardiovascular safety of linagliptin was rigorously evaluated in two large randomized controlled trials. The CARMELINA trial enrolled 6,979 patients with type 2 diabetes and high cardiovascular and renal risk, randomized to linagliptin 5 mg or placebo on top of standard care. After a median follow-up of 2.2 years, linagliptin demonstrated non-inferiority to placebo for the primary composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke (HR 1.02; 95% CI 0.89–1.17). There was no increase in hospitalization for heart failure. The CAROLINA trial compared linagliptin to the sulfonylurea glimepiride in 6,033 patients and demonstrated non-inferiority for the same cardiovascular composite endpoint (HR 0.98; 95% CI 0.84–1.14), with significantly less hypoglycemia in the linagliptin group.

How Should You Store Linagliptin Advanz Pharma?

Proper storage of medications is essential to ensure their continued safety and effectiveness. Linagliptin Advanz Pharma film-coated tablets should be stored at temperatures not exceeding 25°C (77°F). The tablets should be kept in the original blister packaging until ready for use, as this provides protection from moisture. Linagliptin is sensitive to humidity, and exposure to excessive moisture can compromise the integrity and stability of the tablets.

Do not use this medicine after the expiry date which is stated on the blister and the outer carton after “EXP.” The expiry date refers to the last day of that month. Store out of the reach and sight of children. Do not throw away medicines via household waste or wastewater. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help protect the environment.

If you notice any visible changes in the appearance of the tablets (such as discoloration, unusual odor, or physical damage to the tablet), do not take the medication and consult your pharmacist for a replacement. When traveling, keep the medication in your carry-on luggage at a controlled temperature and avoid leaving it in a hot vehicle or exposed to direct sunlight for prolonged periods.

What Does Linagliptin Advanz Pharma Contain?

Active Ingredient

Each film-coated tablet contains 5 mg linagliptin as the active substance. Linagliptin is a xanthine-based molecule with the chemical name 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione. Its molecular formula is C₂₅H₂₈N₈O₂ and its molecular weight is 472.54 g/mol. Linagliptin is a white to yellowish crystalline powder that is very slightly soluble in water.

Inactive Ingredients (Excipients)

The tablet core contains the following excipients:

• Mannitol (E421): A sugar alcohol used as a filler/diluent to give the tablet its bulk.
• Pregelatinized starch (maize): A modified starch used as a binder and disintegrant to help the tablet break apart in the gastrointestinal tract for proper absorption.
• Maize starch: Used as a filler and disintegrant.
• Copovidone: A synthetic polymer used as a binder to hold the tablet together.
• Magnesium stearate: A lubricant that prevents the tablet from sticking to manufacturing equipment during production.

The film coating contains:

• Hypromellose: A cellulose-derived polymer that forms the basis of the film coating, providing protection and facilitating swallowing.
• Titanium dioxide (E171): A white pigment that gives the tablet its base color and protects the active ingredient from light degradation.
• Talc: Used as a glidant in the film coating to improve its application properties.
• Macrogol 6000: A polyethylene glycol used as a plasticizer to make the film coating flexible and prevent cracking.
• Iron oxide red (E172): A coloring agent that gives the tablet its characteristic light pink appearance.

Appearance

Linagliptin Advanz Pharma 5 mg film-coated tablets are light pink, round, biconvex tablets. They are supplied in aluminum/aluminum perforated unit dose blisters. The tablets come in pack sizes of 10, 14, 28, 30, 56, 60, 84, 90, 98, and 100 film-coated tablets, although not all pack sizes may be marketed in every country.